title: Randomized controlled trial to assess the impact of continuous glucose monitoring on HbA(1c) in insulin-treated diabetes (MITRE Study).
abstract: OBJECTIVE
  To determine whether continuous glucose information provided through use of either the GlucoWatch G2 Biographer or the MiniMed continuous glucose monitoring system (CGMS) results in improved glycated haemoglobin (HbA(1c)) for insulin-treated adults with diabetes mellitus, relative to an attention control and standard care group.
  
  
  METHODS
  Four hundred and four adults taking at least two daily insulin injections and with two consecutive HbA(1c) values > or = 7.5% were recruited to this randomized controlled trial (RCT). All were trained at baseline to use the same monitor for traditional capillary glucose testing throughout the 18-month study. The CGMS group were asked to wear the device three times during the first 3 months of the trial and on another three occasions thereafter. The GlucoWatch group wore the device a minimum of four times per month and a maximum of four times per week during the first 3 months and as desired for the remainder of the trial. Trained diabetes research nurses used downloaded data to guide therapy adjustments. Proportional reduction in HbA(1c) from baseline to 18 months was the primary outcome measure.
  
  
  RESULTS
  Neither an intention-to-treat nor per-protocol analysis showed improvement in HbA(1c) in the device groups compared with standard care. For the intention-to-treat analysis, when the standard care group was compared with each of the other groups, this equated to differences in mean relative HbA(1c) reduction (95% confidence interval) from baseline to 18 months of 3.5% (-1.3 to 8.3; GlucoWatch), 0.7% (-4.1 to 5.5; CGMS), and -0.1% (-4.6 to 4.3; attention control).
  
  
  CONCLUSIONS
  The additional information provided by these devices did not result in improvements in HbA(1c) in this population.
authors: Department of Epidemiology and Public Health, University College London, Gower Street Campus, 1-19 Torrington Place, London, UK. debbie.cooke@ucl.ac.uk
authors: D
authors: D
authors: Cooke
authors: S J
authors: SJ
authors: Hurel
authors: A
authors: A
authors: Casbard
authors: L
authors: L
authors: Steed
authors: S
authors: S
authors: Walker
authors: S
authors: S
authors: Meredith
authors: A J
authors: AJ
authors: Nunn
authors: A
authors: A
authors: Manca
authors: M
authors: M
authors: Sculpher
authors: M
authors: M
authors: Barnard
authors: D
authors: D
authors: Kerr
authors: J U
authors: JU
authors: Weaver
authors: J
authors: J
authors: Ahlquist
authors: S P
authors: SP
authors: Newman
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D015190:Blood Glucose Self-Monitoring / Q000295:instrumentation* / Q000523:psychology; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000175:diagnosis; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis*; D006801:Humans; D007328:Insulin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic / Q000295:instrumentation*; D017063:Outcome Assessment, Health Care; D010349:Patient Compliance
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007328:Insulin; C517652:hemoglobin A1c protein, human